MINUTES

Utah Department of Health
Pharmacy and Therapeutics Committee

Thursday, September 21, 2017
7:15 a.m. to 8:45 a.m.
Cannon Health Building
Room 128

Committee Members Present:
Clinton Sheffield, MD
Abril Atherton, PharmD
Bryan Larson, PharmD
Clayton Grace, RPh
Elizabeth Young, PharmD
Keith Tolman, MD
Susan Siegfreid, MD

Committee Members Excused:
Jake Jones, MD

Dept. of Health/Div. of Health Care Financing Staff Present:
Sue Leong, RPh., Pharmacy Director
Alyssa Pitts, RN
Andrea Rico, CPhT
Merelynn Berrett, RN
Robyn Seely, PharmD

University of Utah Drug Regimen Review Center Staff Presenter:
Elena Martinez Alonso, BPharm, MSc MTSI, Medical Writer

Other Individuals Present:
Gregg Gittus, Alkermes
Christy Skibicki, Indivior
Georgette Dzwilewski, Indivior
Jim Sharp, Indivior
Timothy Birner, Alkermes
Kenneth Berry, Alkermes
Jessica Hartung, Braeburn
Chi Kohlhoff, Braeburn
Mark Beacker, Braeburn
Charissa Anne, J&J
Cody Ball, SelectHealth
Lori Howarth, Bayer
Valerie Gonzales, U of U

Meeting conducted by: Committee Chair

1. **Welcome & Housekeeping:** Clinton Sheffield opened the meeting and reminded everyone to sign the rosters.

2. **Review and Approval of August Minutes:** Bryan Larson made a motion to approve the minutes from August. Clayton Grace seconded the motion. Six in favor, Clinton Sheffield abstained. Motion passed.

3. **Drug Utilization Review (DUR) Board update:** The DUR board met last week to discuss Benzodiazepine/Stimulant Mutual Exclusivity, Prior Authorization for Quantity Limits, Prior authorization for Age Limits, Prior Authorization for Hepatitis C, Prior Authorization for Duchenne Muscular Dystrophy, and Pediatric Codeine & Tramadol Use.

4. **Opioid Dependence Treatments:** Elena Martinez Alonso presented a review of Opioid Dependence Treatments. She presented peer-reviewed research regarding the safety and efficacy of each agent, clinical trials, disease-state treatment
    a. **Vivitrol REMS program**
        1. Tim Berner, Senior Director of Medical Affairs at Alkermes reviewed the REMS program for Vivitrol. The purpose of the Vivitrol REMS program is to educate providers of the severe injection site reactions.
    b. **Probuphine REMS program**
        1. Jessica Hartung, Pharmacist, Medical Affairs at Braeburn reviewed the REMS program for Probuphine.

5. **Oral Buprenorphine (sublingual), Buprenorphine/Naloxone, Naltrexone:** Elena Martinez Alonso presented a review of Oral Buprenorphine (sublingual), Buprenorphine/Naloxone, Naltrexone. She presented peer-reviewed research regarding the safety and efficacy of each agent, clinical trials, and disease-state treatment.
    a. **Suboxone REMS program**
        1. Christy Skibicki, Regional Medical Scientist at Indivior reviewed the REMS program for Suboxone.

6. **Public Comment:**
    a. Kenneth Berry, Pharmacist and Medical Science Director at Alkermes provided clinical information for Vivitrol.
    b. Jessica Hartung, Pharmacist, Medical Affairs at Braeburn provided clinical information for Probuphine.
        1. Sue Leong asked what percentage of people have the implant removed. Jessica Hartung followed with Braeburn is only aware of four early removals due to reduced efficacy or discomfort.
        2. Sue Leong ask if there were any patients that had an early removal in the clinical trial; Jessica Hartung followed with there was only one patient in the clinical trial who had an early removal.

7. **Other State Report:** Bryan Larson reported PDL listings for agents in this class in other States' Medicaid programs.

8. **Committee Discussion:** Abril Atherton offered information regarding the products, including the place in therapy for buprenorphine/naloxone combination products vs. buprenorphine standalone products. In most instances, combination products are preferable. For induction and pregnancy, buprenorphine only products may be more appropriate. Bryan Larson stated Probuphine is a medical benefit and not for inclusion on the PDL. Clinton Sheffield made a motion that these agents are equally efficacious. Keith Tolman Seconded. Unanimous Approval. Clinton Sheffield made a motion to have at least one buprenorphine/naloxone combination agent and at least one naloxone alone agent as preferred on the PDL. Abril Atherton seconded. Unanimous approval. Bryan Larson made a motion to change the name of the class to "Opioid Use Disorder Treatments". Abril Atherton seconded. Unanimous approval.

9. **Public Meeting Adjourned:** Clinton Sheffield motioned to close the meeting. Keith

Tolman seconded the motion. Unanimous Approval.

10. **Next meeting is scheduled for** October 19, 2017 Long-Acting Beta-2 Agonist & Glucocorticoid Combinations**.**

Audio recording of all P&T meetings are available online at:
https://medicaid.utah.gov/pharmacy/pt-committee?p=Committee%20Meeting%20Audio%20Recordings